Royal College of Surgeons in Ireland
Browse

Psilocybin for clinical indications: a scoping review

Download (303.68 kB)
journal contribution
posted on 2024-11-26, 09:39 authored by Kim Madden, Breanne Flood, Darren Young Shing, Michael Ade-Conde, Imad Kashir, Melanie Mark, James MacKillop, Mohit Bhandari, Anthony Adili

Background: Psychedelic drugs have been of interest in medicine since the early 1950s. There has recently been a resurgence of interest in psychedelics.

Aims: The objective of this study is to determine the extent of the available literature on psilocybin for medical indications including the designs used, study characteristics, indications studied, doses, and authors' conclusions. We identify areas for further study where there are research gaps.

Methods: We conducted a systematic scoping review of clinical indications for psilocybin, encompassing psychiatric and medical conditions. We systematically searched Medline and Embase using keywords related to psilocybin. We reviewed titles and texts in duplicate using Covidence software. We extracted data individually in duplicate using Covidence software and a senior reviewer resolved all author conflicts. We analyzed data descriptively.

Results: We included 193 published and 80 ongoing studies. Thirty-seven percent of included studies were systematic reviews. Only 12% of included studies were randomized controlled trials. The median number of participants was 22 with a median of 18 participants who had taken psilocybin. Thirty-eight percent of studies reported at least one potential conflict of interest. The most common indication was depression (28%). Also commonly studied were substance use (14%), mental health in life-threatening illness (9%), headaches (6%), depression and anxiety (6%), obsessive-compulsive disorder (3%), and anxiety disorders (3%).

Conclusions: Most studies involving the administration of psilocybin have small sample sizes and the most common focus has been psychiatric disorders. There is a need for high-quality randomized trials on psilocybin and to expand consideration to other promising indications, such as chronic pain.

History

Comments

The original article is available at https://journals.sagepub.com/

Published Citation

Madden K. et al. Psilocybin for clinical indications: a scoping review. J Psychopharmacol. 2024;38(10):839-845.

Publication Date

13 August 2024

PubMed ID

39135496

Department/Unit

  • Undergraduate Research

Publisher

Sage Publications

Version

  • Published Version (Version of Record)